Table Graph
      published meta-analysis   sensitivity analysis   studies

bromhexine in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias clinical deteriorationdetailed resultsLi T, 2020 0.48 [0.01; 27.44] 0.48[0.01; 27.44]Li T, 202010%18NAnot evaluable clinical improvement (21-day)detailed resultsLi T, 2020 2.09 [0.04; 119.96] 2.09[0.04; 119.96]Li T, 202010%18NAnot evaluable hospital dischargedetailed resultsLi T, 2020 10.00 [1.03; 97.50] 10.00[1.03; 97.50]Li T, 202010%18NAnot evaluable mechanical ventilationdetailed resultsLi T, 2020 0.40 [0.04; 3.90] 0.40[0.04; 3.90]Li T, 202010%18NAnot evaluable viral clearance by day 14detailed resultsLi T, 2020 1.00 [0.03; 34.67] 1.00[0.03; 34.67]Li T, 202010%18NAnot evaluable0.220.01.0relative treatment effectwww.metaEvidence.org2024-04-19 05:53 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 688 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons